相关实验视频
Updated: Jun 15, 2025

06:44
A Mouse Model for Chronic Pancreatitis via Bile Duct TNBS Infusion
Published on: February 28, 2021
3.9K
长期的GABA补充 通过GABA受体/素-1/PARs/Akt/COX-2轴调节糖尿病胃肠病
Farzaneh Yazdanimoghaddam1, Hossein Rezazadeh2, Nepton Soltani2
1Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, 4631-19395, Tehran, Iran.
Doklady. Biochemistry and biophysics
|August 28, 2024
概括
胺黄油酸 (GABA) 补充剂通过调节关键蛋白质通路,改善了2型糖尿病大鼠的胃并发症. GABA治疗使蛋白质水平正常化,并增加粘素分泌,这表明糖尿病胃肠道病的治疗潜力.
科学领域:
- 胃肠病学 胃肠病学
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 糖尿病性胃肠病症涉及不太了解的分子变化.
- 关键蛋白质如素-1,PARs,PI3K/Akt和COX-2都与胃功能障碍有关.
研究的目的:
- 为了研究胺黄油酸 (GABA) 对2型糖尿病大鼠蛋白质表达的影响.
- 评估GABA对胃组织中素-1,PAR-1,PAR-2,PAR-3,PI3K,Akt,COX-2,GABAA和GABAB受体的影响.
主要方法:
- 2型糖尿病 (T2DM) 通过高脂肪饮食和Wistar大鼠中的链毒素诱导.
- 鼠分为对照组,T2DM组,胰岛素治疗组和GABA治疗组.
- 蛋白质表达分析通过西式涂抹;由H&E和马森染色分析的组织病理学.
主要成果:
- 在T2DM大鼠中,NOS1降低,COX-2和素-1水平升高.
- GABA和胰岛素治疗使NOS1和COX-2水平正常化.
- 加巴治疗增加了粘素分泌和正常化的GABAA/GABAB受体水平.
结论:
- 通过GABA受体,GABA可以调节素-1/PARs/Akt/COX-2通路.
- 补充GABA显示了改善糖尿病胃肠病并发症的潜力.
- 进一步研究GABA在糖尿病中的治疗作用是有必要的.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
349
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
349
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
281
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
281
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
GPCRs Regulate Adenylyl Cylase Activity
5.4K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.4K
G Protein-coupled Receptors
11.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.6K

